Skip to main content
Fig. 1 | BMC Urology

Fig. 1

From: A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain

Fig. 1

Patient selection flowchart.*Multiple reasons for exclusion may have applied for a single patient, therefore 202 reasons for exclusion are listed; no patients were excluded because of an insufficient pre-index period (i.e. < 12 months’ history) or an insufficient post-index period (i.e. < 12 months’ follow-up); †Mirabegron or an antimuscarinic; eligible drugs listed in Additional file 6: Table S1. 5-ARI, 5α-reductase inhibitor; OAB, overactive bladder

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us